Brokerages Set The Beauty Health Company (NASDAQ:SKIN) Target Price at $5.86

Shares of The Beauty Health Company (NASDAQ:SKIN) have earned a consensus rating of “Reduce” from the twelve analysts that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $5.86.

Several brokerages have recently commented on SKIN. Piper Sandler cut their price target on Beauty Health from $2.50 to $1.50 and set an “underweight” rating on the stock in a research note on Thursday, July 11th. Stifel Nicolaus dropped their price objective on Beauty Health from $4.00 to $2.00 and set a “hold” rating on the stock in a research report on Friday, July 26th. TD Cowen dropped their price objective on Beauty Health from $4.00 to $3.00 and set a “hold” rating on the stock in a research report on Monday, May 13th. Finally, DA Davidson reissued a “buy” rating and issued a $5.00 price target on shares of Beauty Health in a report on Monday, May 13th.

Beauty Health Stock Down 13.5 %

NASDAQ SKIN opened at $1.35 on Tuesday. The company has a debt-to-equity ratio of 10.51, a quick ratio of 5.55 and a current ratio of 6.57. The company has a market capitalization of $166.90 million, a P/E ratio of -1.93 and a beta of 0.96. Beauty Health has a one year low of $1.34 and a one year high of $8.00. The stock has a 50 day moving average price of $1.93 and a 200-day moving average price of $2.84.

Beauty Health (NASDAQ:SKIN) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. The company had revenue of $81.40 million during the quarter, compared to the consensus estimate of $80.56 million. Beauty Health had a negative return on equity of 0.02% and a negative net margin of 20.48%. Beauty Health’s revenue was down 5.7% on a year-over-year basis. During the same period last year, the company earned ($0.17) earnings per share. As a group, equities analysts predict that Beauty Health will post -0.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Beauty Health

Hedge funds have recently modified their holdings of the business. Raymond James & Associates purchased a new position in shares of Beauty Health during the 4th quarter worth $31,000. Sierra Summit Advisors LLC purchased a new position in Beauty Health during the 4th quarter valued at about $856,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Beauty Health in the 1st quarter valued at about $200,000. Global Retirement Partners LLC raised its position in Beauty Health by 359.5% in the 4th quarter. Global Retirement Partners LLC now owns 119,023 shares of the company’s stock valued at $370,000 after purchasing an additional 93,123 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Beauty Health in the 1st quarter valued at about $279,000. 93.26% of the stock is currently owned by hedge funds and other institutional investors.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.